Klox Technologies to present clinical trial results for its innovative AC-1 BioPhotonic platform in Greece and Canada

AC-1 BioPhotonic System, a Non-Invasive Solution for Acne Sufferers, Proven Efficacious and Safe in the Treatment of Moderate to Severe Acne

MONTREAL, June 28, 2013 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX") announced today that it will be presenting the clinically-significant results of its registration trial for its AC-1 BioPhotonic system, an innovative and effective treatment for moderate to severe acne at prominent dermatology conferences in Greece and Canada in the coming days. KLOX will also be presenting scientific information regarding the potential of this same platform for cosmetic applications and skin rejuvenation treatments while in Greece. Please note that KLOX will be issuing a press release in the coming days.

DATEBOOK:

9th World Congress of Cosmetic Dermatology - June 27-30, Athens, Greece

• The impact of BioPhotonics in facial rejuvenation: A prospective randomized investigational trial

Presenter: Dr. Andreas Nikolis, Plastic, Reconstructive and Aesthetic Surgeon, Associate Professor of Plastic Surgery, Division of Plastic Surgery, University of Montreal

Friday, June 28 - 9:30 / 11:00 AM (EET), Session S4.2, Athens Hilton Hotel

• A randomized, prospective, multi-center clinical trial evaluating the efficacy and safety of a novel bioPhotonic platform in the management of moderate to severe acne

Presenters: Dr. Christina Antoniu, Professor in Dermatovenerology, Dermatology Department, A. Sygros Hospital, University of Athens School of Medicine (Athens, Greece) and Principal Investigator of the KLOX registration acne trial and Dr. Andreas Nikolis, Plastic, Reconstructive and Aesthetic Surgeon, Associate Professor of Plastic Surgery, Division of Plastic Surgery, University of Montreal

Sunday, June 30, 12:00 / 1:30 PM (EET), Session S17.6, Athens Hilton Hotel

KLOX representatives will be at kiosk 38 for the duration of the event.

Canadian Dermatology Association 2013 Annual Conference - June 26-30, Quebec City

• BioPhotonics for the treatment of moderate to severe acne - A multi-center, randomized trial

Presenter: Dr. Steven Bernstein, Chief of Dermatology Surgery at Centre hospitalier de l'Université de Montréal (CHUM)

Sunday, June 30, 1:50 PM (ET), Session O-06, Quebec City Convention Centre

KLOX representatives will be at kiosk 43 for the duration of the event.

ON TWITTER
KLOX Technologies corporate account: @KLOXTech

Word Congress of Cosmetic Dermatology: #WCCD2013

Canadian Dermatology Association conference: ‏@CdnDermatology or  #CDAQuebec2013

About KLOX Technologies: Leveraging light-based biophotonic technologies
www.kloxtechnologies.com/en/investor-relations

KLOX is a privately-owned company focused on the development and commercialization of a unique, non-invasive biophotonic technology using a primary device consisting of a multiple LED lighting system that interacts with an oxygen-rich gel containing light-trapping molecules. KLOX's cosmetics and medical devices are destined for the rapidly growing aesthetics, dermatological, tissue repair and dental markets.

SOURCE: Klox Technologies Inc.

Roch Landriault
NATIONAL Public Relations
[phone]
[email protected]